Gene therapy for cystic fibrosis

Expert Opinion on Therapeutic Patents

Volumn 11, Issue 1, 2001, Pages 1-15

  Boyd, A C ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cystic fibrosis (CF); Cystic fibrosis transmembrane conductance regulator (CFTR); Expression vectors; Gene therapy; Lipofection; Lung epithelium; Viral vehicles

Indexed keywords

CARBAMIC ACID DERIVATIVE; CATIONIC SURFACTANT; CHLORIDE ION; COPOLYMER; CRYOPROTECTIVE AGENT; CYCLIC AMP; DETERGENT; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; DNA BINDING PROTEIN; DRUG VEHICLE; GL 67; HUMAN SERUM ALBUMIN; LIPOFECTIN; LIPOSOME; LOW DENSITY LIPOPROTEIN; MACROGOL; MEMBRANE PROTEIN; MICROSPHERE; NUCLEIC ACID; PLASMA PROTEIN; PLASMID DNA; POLYAMINE DERIVATIVE; POLYANION; POLYCATION; SPERMINE CHOLESTERYL CARBAMATE; SPERMINE DERIVATIVE; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN; VIRUS DNA; VIRUS RNA; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CLINICAL PROTOCOL; CONTROLLED STUDY; CYSTIC FIBROSIS; DNA VECTOR; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RESEARCH; DRUG TARGETING; GENE EXPRESSION; GENE MUTATION; GENE TECHNOLOGY; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREGULATION; LUNG DISEASE; MOUSE; NONHUMAN; PATENT; RESPIRATORY EPITHELIUM; REVIEW; TRANSGENE; TREATMENT PLANNING;

EID: 0035184517     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.11.1.1     Document Type: Review

References (87)

1. Cystic fibrosis
2. The genesis of cystic fibrosis lung disease
3. Towards gene therapy for cystic fibrosis: A clinical progress report
4. The extra- and intracellular barriers to lipid and adenovirus-mediated pulmonary gene transfer in native sheep airway epithelium
5. Status of gene therapy for cystic fibrosis lung disease
6. Naked DNA delivered intraportally expresses efficiently in hepatocytes
7. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis
8. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: A double-blind placebo-controlled trial
9. Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis
10. Structure and function of lipid-DNA complexes for gene delivery
11. Gene chemistry: Functionally and conformationally intact fluorescent plasmid DNA
12. Airway delivery of cationic lipid: DNA complexes for cystic fibrosis
13. Comparison of DNA-lipid complexes and DNA alone for gene transfer to cystic fibrosis airway epithelia in vivo
14. An integrin-targeted non-viral vector for pulmonary gene therapy
15. Characterization of lipid DNA interactions. I. Destabilization of bound lipids and DNA dissociation
16. Monomolecular collapse of plasmid DNA into stable virus-like particles
17. Ultrastructural characterization of cationic liposome-DNA complexes showing enhanced stability in serum and high transfection activity in vivo
18. Preparation of surface-modified albumin nanospheres
19. Gene transfer by DNA-gelatin nanospheres
20. Chitosan and its use as a pharmaceutical excipient
21. Targeted integration of a dominant neo(R) marker into a 2- to 3-Mb human minichromosome and transfer between cells
22. Stability of a functional murine satellite DNA-based artificial chromosome across mammalian species
23. Novel generation of human satellite DNA-based artificial chromosomes in mammalian cells
24. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis
25. A Phase 1 study, in cystic fibrosis patients, of the safety, toxicity and biological efficacy of a single administration of a replication deficient, recombinant adenovirus carrying the cDNA of the normal cystic conductance regulator gene in the lung
26. Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus
27. Novel role for E4 region genes in protection of adenovirus vectors from lysis by cytotoxic T lymphocytes
28. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons
29. Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo
30. Lack of high affinity fiber receptor activity explains the resistance of ciliated airway epithelia to adenovirus infection
31. Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia
32. Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector
33. Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector
34. A chimeric Type 2 adenovirus vector with a Type 17 fiber enhances gene transfer to human airway epithelia
35. Modification of an adenoviral vector with biologically selected peptides: A novel strategy for gene delivery to cells of choice
36. Complexes of adenovirus with polycationic polymers and cationic lipids increase the efficiency of gene transfer in vitro and in vivo
37. Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro
38. Incorporation of adenovirus in calcium phosphate precipitates enhances gene transfer to airway epithelia in vitro and in vivo
39. Production of viral vectors for gene therapy applications
40. Diminishing adenovirus gene expression and viral replication by promoter replacement
41. Efficient expression of CFTR function with adeno-associated virus vectors that carry shortened CFTR genes
42. Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus
43. Targeting human T cells by retroviral vectors displaying antibody domains selected from a phage display library
44. Cell-type-specific gene transfer into human cells with retroviral vectors that display single-chain antibodies
45. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
46. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector
47. Lentiviral vectors for gene therapy of cystic fibrosis
48. Human β-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis
49. Pseudotyped human lentiviral vector-mediated gene transfer to airway epithelia in vivo
50. Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect
51. Construction of new retroviral producer cells from adenoviral and retroviral vectors
52. A packaging system for SV40 vectors without viral coding sequences
53. Baculovirus-mediated gene transfer into mammalian cells
54. Efficient transduction of mammalian cells by a recombinant baculovirus having the vesicular stomatitis virus G glycoprotein
55. HSV-1 amplicon vectors - Simplicity and versatility
56. Gene transfer to the nigrostriatal system by hybrid herpes simplex virus/adeno-associated virus amplicon vectors
57. Promoter attenuation in gene therapy: Causes and remedies
58. Development of an epithelium-specific expression cassette with human DNA regulatory elements for transgene expression in lung airways
59. Multiple potential intragenic regulatory elements in the CFTR gene
60. Transcriptional activation by tetracyclines in mammalian cells
61. Novel, high expressing and antibiotic-controlled plasmid vectors designed for use in gene therapy
62. Transcription and polyadenylation in a short human intergenic region
63. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line
64. Biosynthesis and degradation of CFTR
65. Pharmacologic restoration of ΔF508 CFTR-mediated chloride current
66. Functional activation of the cystic fibrosis trafficking mutant ΔF508-CFTR by overexpression
67. Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp70 family of heat shock proteins
68. Partial restoration of cAMP-stimulated CFTR chloride channel activity in ΔF508 cells by deoxyspergualin
69. Molecular targets for existing and novel immunosuppressive drugs
70. Subcutaneous administration of T-epitope sequences of the acetylcholine receptor prevents experimental myasthenia gravis
71. Physiologically responsive gene therapy
72. Anti-inflammatory gene therapy directed at the airway epithelium
73. The effect of mucolytic agents on gene transfer across a CF sputum barrier in vitro
74. bcl-2 inhibits apoptosis of neutrophils but not their engulfment by macrophages
75. Enhanced reporter gene expression in cells transfected in the presence of DMI-2, an acid nuclease inhibitor
76. Binding and uptake of cationic lipid:pDNA complexes by polarized airway epithelial cells
77. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid
78. Loss of CFTR chloride channels alters salt absorption by cystic fibrosis airway epithelia in vitro
79. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease
80. A demonstration using mouse models that successful gene therapy for cystic fibrosis requires only partial gene correction
81. Efficient gene transfer to airway epithelium using recombinant Sendai virus
82. The role of CpG motifs in innate immunity
83. Contribution of plasmid DNA to inflammation in the lung after administration of cationic lipid:pDNA complexes
84. Construction and characterisation of genomic context vectors for CF gene therapy
85. Targeted gene correction: A new strategy for molecular medicine
86. Novel pharmacologic therapies for cystic fibrosis
87. Gene therapy: Cautious optimism